FDA Approves Unknown Drug — IMPAX

IMPAX Pharmaceuticals received FDA approval on February 18, 2004, for NDA ANDA076345, marking a pivotal entry into the generic pharmaceutical market with significant implications for the relevant therapeutic segment. This regulatory clearance strengthens IMPAX’s portfolio of approved products and allows it to capitalize on price erosion opportunities following the patent expiration of the branded reference product.